



4325 Alexander Dr.
Alpharetta, GA 30022-3740 USA

Update on TNF- α
for the treatment of
**Inflammatory
BOWEL DISEASE**

Friday,
December 2, 2005
Miami, Florida

Fontainebleau Resort, Fontaine/Fleur de Lis
12:35 pm – 2:00 pm

Chair:
Russell D. Cohen, MD
University of Chicago Medical Center
Chicago, Illinois

Update on TNF- α
for the treatment of
**Inflammatory
BOWEL DISEASE**

Friday,
December 2, 2005
Miami, Florida

Chair:
Russell D. Cohen, MD
University of Chicago Medical Center
Chicago, Illinois

Registration

No Pre-registration for this symposium is required. Please register for the "2005 CCFA National Research and Clinical Conference – 4th Annual Advances in the Inflammatory Bowel Diseases" at: www.AdvancesInIBD.com

A Luncheon Symposium at the 2005 CCFA National Research and Clinical Conference -
4th Annual Advances in the Inflammatory Bowel Diseases

Scientific Agenda

Lunch will be served

- 12:35 pm Welcome**
Russell D. Cohen, MD
University of Chicago Medical Center
Chicago, Illinois
- 12:40 pm Implications of ACT 1 and ACT 2 data on future therapeutic approaches to Ulcerative Colitis**
William J. Sandborn, MD
Mayo Medical School
Rochester, Minnesota
- 1:05 pm Role of drug compliance in improving treatment outcomes in patients with Ulcerative Colitis**
David G. Binion, MD
Medical College of Wisconsin
Milwaukee, Wisconsin
- 1:25 pm The TREAT registry and its impact on patient management for Crohn's disease**
Russell D. Cohen, MD
University of Chicago Medical Center
Chicago, Illinois
- 1:45 pm Panel discussion/questions**
- 2:00 pm Adjourn**

Symposium Organizer



4325 Alexander Drive
30022 Alpharetta, Georgia
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com

Update on TNF- α for the treatment of Inflammatory BOWEL DISEASE

Friday, December 2, 2005 Miami, Florida Fontainebleau Resort

Educational Objectives

- After successful completion of this activity, participants should be able to:
- » Identify current options for incorporation of infliximab for treatment of patients with Crohn's disease or ulcerative colitis (UC)
 - » Comment on surgical strategies in disease management of patients with IBD
 - » Comment on non-surgical therapeutic strategies in disease management of patients with IBD

Continuing Medical Education

Imedex[®], Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, Inc. designates this educational activity for a maximum of 1.50 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Who Should Attend

This educational program is intended for gastroenterologist, internists, and other health care professionals in active clinical practice involving the management of patients with Inflammatory Bowel Diseases (IBD).

Corporate Support



This symposium is made possible by an unrestricted educational grant from Centocor, Inc. Centocor, Inc. has been assigned meeting space to support an educational offering during the 4th Annual Advances in the Inflammatory Bowel Diseases Conference.

The assignment of meeting space does not imply product endorsement nor does Advances in IBD assume responsibility for the educational content.